Children's Oncology Group
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Children's Oncology Group sits in the top decile of US sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count).
Children's Oncology Group: 342 sponsored US clinical trials, 33 recruiting.
Children's Oncology Group sponsors 342 registered US clinical trials on ClinicalTrials.gov, 33 of them currently recruiting, and 260 completed. 103 of these trials are in Phase 3-4 (later-stage) and 128 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 12 trials.
Top-decile sponsor footprint
Children's Oncology Group ranks in the top decile of sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
260 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (99.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
342 total, page 6 of 7
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
NCT00070187
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
NCT00898404
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
NCT00059839
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
NCT00898079
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
NCT00070473
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
NCT00027846
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
NCT00048984
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
NCT00028795
Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia
NCT00056069
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
NCT00022126
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
NCT00003958
Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia
NCT00021242
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT00028899
Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201
NCT00028509
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT01005277
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT00031824
STI571 in Treating Patients With Recurrent Leukemia
NCT00004932
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
NCT00003750
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
NCT00445718
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
NCT00006734
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
NCT00006760
Registration and Informed Consent Study for the Childhood Cancer Research Network
NCT00433394
Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT00006462
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
NCT00017368
Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
NCT00005602
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
NCT00004188
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
NCT00006024
Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor
NCT00006461
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
NCT00008424
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
NCT00006463
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
NCT00003070
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
NCT00006095
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
NCT00004228
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
NCT00005945
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00005596
Quality of Life in Children Treated for Cancer
NCT00005881
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
NCT00003811
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00005585
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00005603
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
NCT00004056
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
NCT00004010
Irinotecan in Treating Children With Refractory Solid Tumors
NCT00004078
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
NCT00003937
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma
NCT00003955
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
NCT00003935
Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors
NCT00003846
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
NCT00003593
Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia
NCT00003933
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 75 |
| Phase 3 | 103 |
Therapeutic Areas
What is open in the Children's Oncology Group pipeline
33 recruiting of 342 indexed (10% open); 260 completed (76%).
Phase mix: 103 late (III/IV) vs 128 early (I/II) (balanced across stages).
Top condition: Leukemia (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Children's Oncology Group: open-pipeline peers nationwide
Peers matched on 342 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Children's Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 342 trials (± recruiting share)
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Montefiore Medical Center · 345 trials · 19% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Sanofi · 10% recruiting · 713 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
Related
What to do with this Children's Oncology Group page
342 registered trials is a research-attention snapshot, not an endorsement of Children's Oncology Group or any single study.
- 33 of Children's Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Children's Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Children's Oncology Group pipeline card: 342 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.